The closure of the de minimis loophole – which went into effect at midnight – stops the descent into eCommerce lawlessness characterized by the rise in platforms like Temu and Shein, and the fact that judgment-proof overseas retailers now make up the majority of vendors on Amazon’s U.S. store.
Ruling Clears the Way for Retroactive Tariffs on Billions in Illegally Imported Chinese Solar Equipment
America is dangerously reliant on high-risk foreign suppliers for essential generic drugs, especially APIs concentrated in China and India. That over-reliance has already triggered preventable crises, such as nationwide chemotherapy shortages when a single overseas plant shut down.
Today’s action to directly target the midstream layer—rods, pipes, wires, connectors, and other semi-finished copper products that are essential to our economy and national security is extremely welcome. Combining the Section 232 action with the use of the Defense Production Act to ensure a robust supply of copper scrap for recycling is extraordinary.
America’s generic drug supply is at a crisis point. As detailed in previous reports, the United States is dangerously reliant on a high-risk imported drug supply, and today’s widespread drug shortages stem not from shipping delays or unexpected demand—but from a collapse in domestic production.
On July 17, at an event at New York University, a member of the Federal Reserve Board of Governors, Christopher Waller, said that tariffs are not inflationary. “Tariffs are one-off increases in the price level and do not cause inflation beyond a temporary surge,” he said.
Any Senator who supports an amendment to remove or weaken the FEOC Excise Tax is directly endorsing China’s solar industry—dominated by companies using slave labor, powered by coal, and compromised by severe cybersecurity risks.
Last year, it wasn’t even in the Top 10. This year, they’re number one. General Motors was ranked as the most China-exposed U.S. multinational by Strategy Risks, a political risk consultancy in New York.
America is facing a growing crisis in its medical system — not from a lack of talent or innovation, but from a breakdown in the control, safety and supply of essential medicine. Our growing reliance on imports is now driving serious drug shortages, destabilizing supply chains and increasingly making medications unsafe.
In the U.S. today, frontline cancer treatments are being rationed. ERs are short on sedatives. Amoxicillin—one of the most prescribed antibiotics in the country—has been in critical shortage. These are not temporary disruptions. They reflect a structural breakdown caused by the erosion of America’s pharmaceutical manufacturing base and a decades-long surge in generic drug imports.
